BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...Pericle, who resigned. Patti was president and CEO of Aviragen Therapeutics (NASDAQ:AVIR); he also co-founded Inhibitex Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...its share price and market cap. The 2012 acquisition of a second-in-class HCV molecule from Inhibitex Inc....
...to first-in-class cancer immunotherapies Yervoy ipilimumab and ex-Japan rights to Opdivo nivolumab 1/7/12 - Acquired Inhibitex Inc....
...got short-lived boosts after two 2012 deals that gave it second-in-class HCV candidate INX-189 from Inhibitex Inc....
BioCentury | Jun 16, 2014
Strategy

Nucleotide arms race

...a short-lived bump in early 2012 when Bristol-Myers Squibb Co. (NYSE:BMY) acquired another HCV play, Inhibitex Inc....
...Gains 37% to $9.66 after Bristol-Myers Squibb Co. (NYSE:BMY) says it is buying HCV company Inhibitex Inc....
BioCentury | Aug 12, 2013
Financial News

Synergy financial update

...trial to treat Varicella zoster virus (VZV) infection (shingles), through its $2.5 billion takeover of Inhibitex Inc....
BioCentury | Aug 9, 2013
Financial News

ContraVir seeking public listing

...trial to treat Varicella zoster virus (VZV) infection (shingles), through its $2.5 billion takeover of Inhibitex Inc....
BioCentury | Apr 29, 2013
Product Development

Plan B in HCV

...Bristol-Myers Squibb Co. 's HCV ambitions did not die with Inhibitex Inc. 's INX-189. The pharma believes...
BioCentury | Feb 25, 2013
Finance

Ready to go solo

...Sciences Inc. (NASDAQ:GILD) acquired Pharmasset Inc. for $11 billion and Bristol-Myers Squibb Co. (NYSE:BMY) bought Inhibitex Inc....
...was probably talking to the same companies who subsequently went on to acquire Pharmasset and Inhibitex...
BioCentury | Jan 14, 2013
Finance

Darwin's delight

...the biggest biotech takeouts of 2012, Bristol-Myers Squibb Co. paid $2.5 billion for HCV play Inhibitex Inc....
BioCentury | Nov 19, 2012
Company News

Biota Pharmaceuticals management update

...Patti as EVP of corporate development and strategy, formerly SVP of R&D and CSO of Inhibitex Inc....
...acquired; and Russell Plumb as CEO and a director, formerly president, CEO and CFO of Inhibitex Inc....
BioCentury | Sep 10, 2012
Product Development

Inhibitex's Tox

...Squibb Co. may have looked past in vitro safety signals in a rush to add Inhibitex Inc....
...pharma declined to discuss what data it considered in its due diligence prior to acquiring Inhibitex...
...the firm's public portfolio and has followed the HCV space closely. venBio was long on Inhibitex...
Items per page:
1 - 10 of 261
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...Pericle, who resigned. Patti was president and CEO of Aviragen Therapeutics (NASDAQ:AVIR); he also co-founded Inhibitex Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...its share price and market cap. The 2012 acquisition of a second-in-class HCV molecule from Inhibitex Inc....
...to first-in-class cancer immunotherapies Yervoy ipilimumab and ex-Japan rights to Opdivo nivolumab 1/7/12 - Acquired Inhibitex Inc....
...got short-lived boosts after two 2012 deals that gave it second-in-class HCV candidate INX-189 from Inhibitex Inc....
BioCentury | Jun 16, 2014
Strategy

Nucleotide arms race

...a short-lived bump in early 2012 when Bristol-Myers Squibb Co. (NYSE:BMY) acquired another HCV play, Inhibitex Inc....
...Gains 37% to $9.66 after Bristol-Myers Squibb Co. (NYSE:BMY) says it is buying HCV company Inhibitex Inc....
BioCentury | Aug 12, 2013
Financial News

Synergy financial update

...trial to treat Varicella zoster virus (VZV) infection (shingles), through its $2.5 billion takeover of Inhibitex Inc....
BioCentury | Aug 9, 2013
Financial News

ContraVir seeking public listing

...trial to treat Varicella zoster virus (VZV) infection (shingles), through its $2.5 billion takeover of Inhibitex Inc....
BioCentury | Apr 29, 2013
Product Development

Plan B in HCV

...Bristol-Myers Squibb Co. 's HCV ambitions did not die with Inhibitex Inc. 's INX-189. The pharma believes...
BioCentury | Feb 25, 2013
Finance

Ready to go solo

...Sciences Inc. (NASDAQ:GILD) acquired Pharmasset Inc. for $11 billion and Bristol-Myers Squibb Co. (NYSE:BMY) bought Inhibitex Inc....
...was probably talking to the same companies who subsequently went on to acquire Pharmasset and Inhibitex...
BioCentury | Jan 14, 2013
Finance

Darwin's delight

...the biggest biotech takeouts of 2012, Bristol-Myers Squibb Co. paid $2.5 billion for HCV play Inhibitex Inc....
BioCentury | Nov 19, 2012
Company News

Biota Pharmaceuticals management update

...Patti as EVP of corporate development and strategy, formerly SVP of R&D and CSO of Inhibitex Inc....
...acquired; and Russell Plumb as CEO and a director, formerly president, CEO and CFO of Inhibitex Inc....
BioCentury | Sep 10, 2012
Product Development

Inhibitex's Tox

...Squibb Co. may have looked past in vitro safety signals in a rush to add Inhibitex Inc....
...pharma declined to discuss what data it considered in its due diligence prior to acquiring Inhibitex...
...the firm's public portfolio and has followed the HCV space closely. venBio was long on Inhibitex...
Items per page:
1 - 10 of 261